Clinical data indicate that peroxisome proliferator-activated receptor-gamma (PPARγ) is upregulated in the tumor in 40% of patients resistant to pembrolizumab, and high PPARγ expression is associated with a lower survival rate [57]. This evidence concerns the gene PPARG and neoplasm.